Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. - Wikidata - awgldk - TriplyDB

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

http://www.wikidata.org/entity/Q40390558

about

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications Farnesyl transferase inhibitor resistance probed by target mutagenesis Midostaurin: an emerging treatment for acute myeloid leukemia patients Targeting cancer with kinase inhibitors Targeted therapies in CLL: mechanisms of resistance and strategies for management Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib Secondary mutations as mediators of resistance to targeted therapy in leukemia FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.The Biology and Targeting of FLT3 in Pediatric Leukemia.Phase I study of sorafenib in patients with refractory or relapsed acute leukemias The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.The Future of Targeting FLT3 Activation in AML.Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations Current therapeutic strategies for acute myeloid leukaemia.Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

P2860

Q24617091-CA43CD70-CB01-4864-93EE-2487238149A4 Q24684154-9B594AA0-A2C7-455C-9B77-0BA533BBC697 Q26749271-554572D5-EBB2-451B-A392-B7832CD3DA69 Q26865765-1036CCE7-0F95-40E8-86D0-D0688435D549 Q27002528-F62AD654-B997-4752-9D79-832B5A26F539 Q27851579-D3AE3121-22DB-474D-9672-B306313985C1 Q27851628-1A7EE9E5-0311-4C8D-8957-B18B0A2CDC2C Q27851767-2478F0C4-40FA-4356-9023-346395DCBA0F Q27852087-CAAB3DC0-40DC-4230-8D22-EA5409B49BF5 Q27853011-EE406FEF-1739-4A53-AEE2-60BF74BE0694 Q28087213-9A0898B5-B213-433F-A825-C807E3AE2167 Q28289859-6AF408FD-9EA9-4F9C-AC53-1D5C2D5CB890 Q28477269-07FBD8FD-2F75-4F36-B37A-A95CEB24266D Q28539032-B835EF69-7C81-4EFB-894E-9670AFCD1C63 Q30313615-D76BCCC1-653F-41A0-B052-7C23601ACADB Q33828409-F06B052F-8860-495C-ADDE-8DCB3327A683 Q33913329-4D5E5F73-8445-46BE-9B56-F9C743CD4F92 Q34011740-9C89322F-F11C-4973-A792-73F34F1F1BFE Q34095013-D77816A1-9258-45EE-BA59-1017181CEE30 Q34229555-0C2C9138-62D5-40D3-9F91-263B9860C205 Q34451540-7586D1D1-36A6-4001-BEDB-BAEA6882B66E Q34465221-C7925C99-6FA3-4583-951B-CE77FA645A34 Q34476246-0C12C52D-9F46-48EC-BF66-CA57E4D7D293 Q34555386-52B82C4D-4229-4743-BA12-DC228B83CA42 Q34754344-A15E4040-060A-4D67-B96C-EED8E0F5196A Q34972671-04A3783C-0145-48A6-8D75-E1C975F3290C Q34993145-7AC45771-4E68-42D3-9A3C-327391E16C07 Q35016157-30089394-AC30-4C8A-A6BD-A85316F28074 Q35114397-21AECB4B-C3C0-486A-9BA1-73A3CCFE401A Q35615901-060A5160-8DB0-4B3E-B346-456389B72AE6 Q35740058-1DBD1E85-B253-405C-875D-9FDC820AF23E Q35865681-04F0C84A-26BF-4C45-B4A3-726BA27B6D8C Q35979385-73B52604-617F-45B0-A994-20095BAF4B23 Q36129030-4379ED04-7D28-42ED-935A-F8EA0498999D Q36318153-26638A3E-F86F-40DB-9A05-ED8A797371B8 Q36366670-B7702787-42F0-4BC1-8506-2E1315C458B0 Q36469916-06367698-9F06-47ED-921A-E3BB736A5283 Q36481950-BCBD3AA5-F09A-40F4-A9EB-D488306EDE33 Q36539598-5BD192CF-A2F6-49C0-9021-487BDA92BBEB Q36823385-2093B55F-FD9D-4056-9D92-926958EFCCB7

P2860

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

http://www.wikidata.org/entity/Q40390558

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Clinical resistance to the kin ...... e FLT3 tyrosine kinase domain.

@en

type

label

Clinical resistance to the kin ...... e FLT3 tyrosine kinase domain.

@en

prefLabel

Clinical resistance to the kin ...... e FLT3 tyrosine kinase domain.

@en

P1433

Q40390558-67AF58C4-ECC7-4F23-B081-6DDA941C4BDB

P1476

Q40390558-39D1433C-A306-49A5-9762-EB7CD469F532

P2093

Q40390558-126294B6-312D-4E96-8261-78B1EBECC45E

Q40390558-2BB7669C-BF0F-4A90-AAD6-88E536BDF705

Q40390558-31F568D3-4070-49A5-94BE-2B8D9D5D841E

Q40390558-3521128F-1F8D-4EEA-AC8F-B253E45E803B

Q40390558-45026EA8-069C-4529-8FC6-CD5B4BF3E3FD

Q40390558-45D2AC89-7351-4293-B594-0D0F40E688D8

Q40390558-56D002F2-9410-47C0-A010-4418793C2B6A

Q40390558-7EBB3E3B-5F97-4BBF-BE7C-B09930353081

Q40390558-8FB1D07A-B54E-46D3-A397-9EC47451B082

Q40390558-97D4F60D-7B6B-472B-A299-69A4B58DB707

P304

Q40390558-B657C401-BE66-4977-875C-BC30E68D18D6

P31

Q40390558-AB488EBE-0076-4E8B-A7C1-3FDDED24B9D7

P356

Q40390558-6E5C0138-D418-4BA6-A607-7062A06A81ED

P407

Q40390558-6465274A-7632-411D-B83F-0FD478835438

P433

Q40390558-DFCEB758-70A9-4EA3-8A25-814B37B85ABD

P478

Q40390558-A2EBCE0E-7DA1-439C-AEE6-9A09FC6CB9D5

P50

Q40390558-994F65D4-7073-4E83-AC36-55F93A474F8D

Q40390558-B36FD82C-65B7-4165-BDE8-04EB708A530A

P577

Q40390558-E0FFA688-7317-404A-898D-9229CAB608A1

P5875

Q40390558-4AD482CA-61AC-4FE4-A94E-B7A4D821B2B6

P698

Q40390558-E135623B-0186-42E3-A997-97D19754326F

P921

Q40390558-AE762DAB-33B1-42F6-8CF6-859F6733C054

P356

BLOOD-2005-06-2469

P1433

P1476

Clinical resistance to the kin ...... e FLT3 tyrosine kinase domain.

@en

P2093

Christian Brandts

http://www.w3.org/2001/XMLSchema#string

Christoph Huber

http://www.w3.org/2001/XMLSchema#string

Daniel B Lipka

http://www.w3.org/2001/XMLSchema#string

Eric Feldman

http://www.w3.org/2001/XMLSchema#string

Fian K Solem

http://www.w3.org/2001/XMLSchema#string

Florian Heidel

http://www.w3.org/2001/XMLSchema#string

Frank Breitenbuecher

http://www.w3.org/2001/XMLSchema#string

Gary J Schiller

http://www.w3.org/2001/XMLSchema#string

Hubert Serve

http://www.w3.org/2001/XMLSchema#string

Johannes Roesel

http://www.w3.org/2001/XMLSchema#string

P304

293-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-06-2469

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Gerhard Ehninger

P577

2005-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7611061

http://www.w3.org/2001/XMLSchema#string

P698

16150941

http://www.w3.org/2001/XMLSchema#string

P921